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Abstract: 
This article is based on an exhaustive review of empirical 
evidence from secondary sources of information seeking to 
answer the research question: What are the main obstacles 
raised by the Institutional and Regulatory framework for 
R&D activities in Colombia’s biotechnology sector?  
The main findings indicate: (I) that there is a flawed 
competitive environment that tends to create oligopolies and 
other scenarios that facilitate the hoarding of information and 
knowledge and prevent access by many scientists to relevant 
new information breakthroughs, thus generating material 
asymmetries between the scientific communities of 
developed and developing countries; and (II) that other 
obstacles, generally associated with government 
shortcomings, produce non-financial transaction costs in 
terms of time and administrative processes, that represent 
significant impediments to the development of the 
biotechnology industry and which, in the Colombian case, 
have slowed progress in the sector.  
Keywords: Biotechnology, Property Rights, Public Policy, 
Institutional Environment. 
 
 
1. Background 
 
 
There is an important aspect that highlights the relevance of this investigation: Questions related to 
progress and technological innovation occupy an essential place on governmental agendas. Despite the efforts 
to advance in this subject, there are elements from the institutional and regulatory environment that neutralize 
any determination from the economic policy, and impede that improvements in the biotechnology sector 
permeate the society to improve its well-being and quality of life. Regardless of the importance of the subject, 
there is a large knowledge gap, both in number of researches in the topic as in the scenarios that such studies 
have been applied, like the case of Latin America, and more specifically in the Colombian case, that impede to 
establish its findings as facilitators for future relations between public policy, the government and the private 
sector, to improve the developments in biotechnology. 
 
In recent years the biotechnology industry has experienced significant rates of technological 
development and created a range of new applications, with an increase in the production of high value-added 
pharmaceuticals, cosmetics and chemicals. Increased competition between biotechnology companies has 
become more noticeable and there is a tendency to develop clearer strategic lines of action in order to survive 
and grow in a market characterized by asymmetric competitive forces. Some studies suggest a decline in market 
barriers for biotech products despite the persistence of other types of deterrents in the industry (OECD - Festel 
Capital, 2010).  
 
A major market failure identified in this industry is a tendency towards the formation of oligopolies 
and other scenarios characterized by imperfect competition. The industry’s market structure comprises three 
different types of organizations: (I) small start-ups; (II) medium-sized companies; and (III) major 
multinationals. Their operations can be highly specialized, creating only a small portion of the total value added 
along the production chain, or their production can be diversified (OECD - Festel Capital, 2010). In this regard, 
there is certain concern about the effect of management on the protection of intellectual property, which "can 
help strengthen monopolies, and eventually exclude small businesses from the market, especially in developing 
countries" (Defrancesco, E. and Runge F., 2006). It is known, for example, that in 1995 alone, European and 
U.S. companies invested USD 3.5 billion in acquiring smaller biotech companies (Pinilla E., 2004).  
 
Nowadays, as noted by Juma, C. and Honca, D. (2002), the market is the domain of the private sector 
multinationals in the US and Europe, despite the participation of other countries which, notwithstanding the 
presence of a large number of small businesses whose number easily exceeds that of the multinational 
companies, hold a minor market share in a scenario where multinationals represent an oligopolistic structure 
and command the largest proportion of worldwide sales, according to market share data.  
 
In the Colombian case, according to information obtained from Colciencias (2008), local companies 
dominate the market with a 73% share. However, the majority of these companies are small in size, with almost 
50% of them having less than 50 employees. These are followed by 28% that are defined as medium-sized. 
Only 30 laboratories (22% of the country’s total) have more than 200 employees, and these generate 73% of 
the sector’s jobs and contribute 83% of total production. It is the multinationals who actually control the market.  
 
One of the negative consequences of the majority presence of multinationals in the Colombian market 
is associated with their modus operandi. In general, these businesses only import processed products that are 
locally packaged for sale to the Colombian market. Only one of the multinational laboratories has a production 
plant in the country, the rest import all their products ready-made by their parent companies or plants located 
in other countries. This situation goes beyond a simple appropriation of the market; it creates an environment 
that prevents the generation of spillover effects, particularly in terms of knowledge and technology transfer, 
that discourage the development of the domestic biotechnology industry.  
 
Patents, while being a key incentive to investment in innovation, are also a source of monopoly power 
(Pearse, N., 2007). In general, monopolies of information and know-how, in the form of patents, deprive many 
researchers of access to relevant information that will further scientific advances (Defrancesco, E. and Runge 
F., 2006). This situation is prone to generate strong asymmetries of information between the scientific 
communities of developed and developing countries.  
 
One sector that aptly reflects such a monopolistic situation is the Colombian seed market, where four 
multinationals (Dupont, Sygenta, Monsanto and Bayer Cropscience) clearly dominate the market, followed by 
3 local companies (Semillas la Pradera, Semillas Andree and Procampo S.A.) (Colciencias, 2008). It is further 
suggested that the management of intellectual property rights has favored the creation of monopolies and in 
certain cases that patent management has stimulated the concentration of developments in different fields 
(Pinilla E., 2004). In any event, there is a strategic behavior common to large companies whereby they seek to 
concentrate knowledge, capital, technology and patents. Experts also comment that the struggle for patents is 
essentially unfair (Pinilla E., 2004).  
 
In Latin America, the main obstacles to progress in countries such as Argentina, Brazil and Colombia 
are associated with government and market shortcomings arising from:  
 
1) The scarcity of resources, despite public funds being available that are specifically intended to promote 
scientific and technological research in fields covered by biotechnology. This circumstance generates 
extra costs in terms of time and administrative processes, that make it more difficult to obtain financing 
that is suited to the specific industry and its business environment. For instance, in 2012, Colombia 
spent 0.449% of its GDP on scientific and technological activities and 0.17% on research and 
development (Colombian Observatory for Science and Technology - OC&T - 2012), significantly less 
than the target of 1%. In 2013, Colciencias (Colombia’s Administrative Department of Science, 
Technology and Innovation) suffered a major institutional crisis due to significant funding cuts.  
2) Difficulties in increasing investments in infrastructure and applied research, and other financial 
constraints (Zylberberg, C. et al., 2012);  
3) Lack of coordination between academia, the private sector and the government aimed at channeling 
research activities towards strategic areas and focusing research on satisfying market needs. 
Asymmetric information from these agents has hampered the arrival of new forms of private local and 
foreign capital.  
4) Excessive costs in terms of administrative red tape for importing a wide variety of biotechnological 
inputs and difficulties in marketing scientific discoveries.  
5) A regulatory framework that hinders investigation, including laws and procedures in sectors such as 
pharmaceuticals, herbal medicine, nutraceuticals, cosmetics and personal care that generate 
administrative costs in terms of time (Colciencias, 2008)  
6) Shortage of partnerships between local actors and outsiders, (despite the initiatives promoted by the 
Colombian government and, in the case of Argentina and Brazil, MERCOSUR cooperation 
agreements), which can be associated with: lack of coordination, procurement information and highly 
specialized expertise; uncertain quality of the partner and its contributions; the need to monitor the 
performance of distribution areas; control over the proper handling of highly specialized information; 
foreseeing contingencies in contracts; the possibility of opportunistic behavior in the interaction of 
cooperating agents with notable asymmetries of power between them, among others.  
7) In many cases, the absence of a specialized body in multidisciplinary areas that mitigates coordination 
problems and asymmetric information and that expedites cumbersome procedures for research centers 
and biotechnology companies.  
 
Generally speaking, these situations denote coordination failures and serve to increase investors’ 
uncertainty and perception of risk. (González, C. et al., 2007).  
 
Apart from the foregoing, the biotech industry faces many major challenges and obstacles to its 
development, associated with:  
 
1) Acceptance by consumers of products with potential impacts on human health, the environment and 
economic dynamics. This necessarily implies compliance with biosafety regulations that may 
occasionally act as market barriers, but which in turn are recognized more by large biotech companies 
as being critical to their avoiding negative actions being brought or taken against them, to maintaining 
political support of the industry and ensuring the sustainability of their businesses.  
2) Acceptance of biosecurity, sustainability and other principles established in biosecurity protocols in the 
industry (such as the case for Colombia of the Cartagena Protocol), based on conservation, preservation 
and reduction in the risk of disease in the biodiversity, are of fundamental importance in countries with 
similar biodiversity characteristics.  
3) Technical risks inherent to the biotechnology industry, due to the complexity of the underlying 
activities.  
4) Regulation. Biotechnology is one of the most highly-regulated industries in the world and its 
development is subject to numerous rules and procedures for achieving marketing approval, which 
may also change over time, creating uncertainty regarding regulatory processes.  
5) Financial. Biotechnology is highly capital intensive and companies in this sector depend heavily on 
their ability to access capital funding in order to develop their products.  
 
2. The institutional framework applied to the biotechnology market in Colombia 
 
Companies’ potential for development depends largely on the institutional environment within which 
they operate. This is because of the administrative procedures, legal requirements, need to find sources of 
financing and the coordination of a large number of agents, among other aspects, that are required to reach the 
commercialization stage. In this sense, the institutions of control established in the market where the company 
is located can exert a powerful influence.  
 
Today the government of Colombia recognizes the strategic importance of biotechnology as a future 
engine of economic growth for the country (Castellanos, O. et al., 2011). Consistent with this goal, it has sought 
to develop different institutional mechanisms to foster growth in the sector. The relevance of public policy in 
biotechnology has also been highlighted in national policy documents whose purpose is to generally improve 
the technical, economic and institutional conditions for the development of the sector (Foros Semana, 2011).  
 
The objectives of such policies contemplate: (i) creating the legal, economic, technical and institutional 
conditions for attracting public and private resources towards the business development of products based on 
the country's immeasurable biodiversity; (ii) improving the institutional capacity required for the commercial 
development of biotechnology; (iii) developing a set of economic instruments to attract public investment in 
the development of companies and biotech products; (iv) adapting and reviewing the regulatory framework 
related to the access to genetic resources, production and marketing of biotech medications and herbal products; 
and (v) evaluating the creation of the National Bioprospecting Enterprise.  
 
In this regard, feasibility studies have been undertaken for the creation of the National Bioprospecting 
Enterprise and plans are afoot for the creation of an inter-sectoral committee that will report to the different 
government entities whose authorization is required for the development of biotechnology. Two national centers 
are also proposed: (i) the National Center for Genomics, the country’s administrative body for collecting genetic 
information and massive parallel DNA sequencing; (ii) the Center for Bioinformatics and Computational 
Biology in Manizales, which processes the information collected by the first named (Foros Semana, 2011). The 
Business Development and Foreign Trade Bank of Colombia (Bancóldex) is involved in the management of 
seed capital generated through royalties.  
 
The declared intention of the institutional framework developed by the Colombian government is that 
the establishment environment should be conducive to public and private national research centers and access 
to new technologies and strategic alliances, in conjunction with international cooperation projects, bringing 
together academics and domestic and foreign business and financial agents, with a view to achieving an overall 
integration of the market, thanks to the joint participation of the public and private sectors (Colciencias, 2008).  
 
However, the real-life scenario shows signs of inconsistencies between the rhetoric and reality, which 
has resulted in quite modest achievements in R&D (González, J., 2011). For instance, there have been 
significant cutbacks in Colciencias budgetary resources in recent years, and this has generated a dynamic 
dispute among the regions regarding the General System of Royalties, largely due to the government’s 
insistence that Colciencias define priorities, which, per se, is incompatible with the agency’s stated mission. 
Furthermore, it is feared that the resources will be lost if they are destined to local projects, and will end up 
having no impact on the consolidation of R&D.  
 
Empirical cases demonstrate the complexity of the procedure as well as the difficulties involved in 
appropriately informing those interested in biotechnological developments. The absence of an institutional 
environment, whose structure could take the form of offices acting as administrative units and links, is sorely 
noted. Excessive red tape; lack of clarity as to the procedural requirements; excessive lead times for compliance 
with each of the stages; uncertainty as to the total time required for the completion of all the processes involved; 
processing delays caused by entities directly or indirectly related to the procedure; additional requirements not 
established in the prerequisites and / or lead times that do not correspond to those specified, among others, are 
just some of the most important circumstances generating extra / unplanned transaction costs in terms of time 
and money that most affect the smaller companies (MSMEs), which are a majority in Colombia, to the extent 
that they lack the human and financial resources needed to deal with all of them. These difficulties therefore 
encourage imperfect competition since the MSMEs are essentially subject to the same procedures as the 
multinationals, whose power in terms of resources is obviously far greater.  
 
According to the study conducted by Innpulsa Colombia, (2013), other limitations along the 
production chain of technology-related goods and services in Colombia are evident, namely:  
 
1) Lack of coordination among key agents in the development of this industry, resulting from an absence 
of the institutions and entities that should be performing this function.  
2) Difficulties in amending the existing legislation which hinders research and development in this area. 
For instance, it has not been possible to establish a general framework, therefore obliging the researcher 
to apply for individual permits for each active ingredient, with a consequent proliferation of 
bureaucratic costs, waste of time and investor uncertainty.  
3) Paperwork, bureaucratic costs and time losses involved in accessing existing, but insufficient, funding 
sources.  
4) Multiple difficulties in achieving compliance with agreements, and even legal barriers against meeting 
the political commitments made by the National Council on Economic and Social Policy in CONPES 
3697 of 2011 (Policy for the Commercial Development of Biotechnology through the Sustainable Use 
of the Biodiversity)..  
5) Lack of coordination and sharing of information among institutional agents due to the absence of 
suitable incentives, collectively preventing full usage of the capital (human, technological and 
knowledge) available in the universities to meet the needs of the sector. The universities also lack the 
guidelines needed to assess the knowledge and technology they develop.  
6) Complex bureaucratic processes that have to be overcome to access biobanks.  
7) Problems of uncertainty and risk. As an example, the Common Provisions on Industrial Property 
applicable in Colombia (governed by Andean Community Decision 486), significantly limit the scope 
of protection of potential intellectual property. Furthermore, the regulations on the distribution of 
royalties create a loophole in the designation of who actually owns the industrial property rights 
generated with these resources.  
8) Problems of asymmetric information and uncertainty regarding the potential negative effects of 
biotechnology developments that have contributed to "the poor image of the biotechnology sector and 
social rejection due to their association with excessive genetic manipulation".  
9) Imperfect information leading to: difficulties in identifying suitable partners in academia; time costs 
resulting from slow procurement under Law 80 of 1993 (issuing the general rules for public 
procurement), which hinders access by innovative Colombian MSMEs to public contracts.  
10) Higher administrative costs in export processes due to controls imposed by the National Institute for 
Food and Drug Monitoring (INVIMA) – and on entities not certified by the International Laboratory 
Accreditation Collaboration (ILAC), among others.  
 
The following are among the factors influencing the scarcity of resources: investors’ strong aversion 
to risk; the opportunity costs of investing in real estate and difficulties in accessing public resources arising 
from the "precarious flexibility of convocations in areas such as the type and size of bankable projects, deadlines 
(open window)". Similarly, it should be noted that not all sources of funding, whether they are public or private, 
will work or be readily available for all stages of the projects (research, development, marketing, etc.). The 
researcher and / or entrepreneur must know which type of funding source best suits the particular stage of the 
project.  
 
Research conducted by Innpulsa Colombia (2013; p.111) into the potential of the country’s 
biotechnology has found that the fiscal incentives available for research and development are not consistent 
with the characteristics of biotechnology projects, which have negative cash flows over a number of years; 
moreover, the complexity of access to them makes them unattractive to MSMEs. 80% of the companies 
questioned believe that public funding is inadequate and fails to meet the needs of this sector. It is also slow, 
and plagued with unnecessary red tape (p.81). On the demand side, an overwhelming majority of companies 
stated that the main limitations to incorporating biotechnological solutions in their products, apart from funding, 
are ignorance as to the possible choices available, shortage of specialized suppliers and a lack of qualified 
personnel (p.94). Companies requiring specific information for moving ahead with the development of new 
processes, based on research protected by patents granted in the US, (considered the largest scientific 
bioprospecting market in the world), face other sets of difficulties.  
 
Research has also found that institutions such as the Francisco José de Caldas Fund (a financing arm 
of Colciencias) operate very slowly meaning that prompt and simple access to funding is impossible, making 
the process unattractive for many small- and medium-sized firms. Similarly, access to the resources of the 
general royalty system is very restricted due to the subordination of project structuring to the general adjusted 
methodology, and to the determination of the Collegiate Decision-Making Authority (OCAD), taken according 
to regional impact criteria, among others. 
  
3. Strategies implemented to achieve progress in the biotechnology sector 
 
Upon reviewing the business strategies employed to promote the development of the biotechnology 
sector, it was found that each country develops its own differentiated strategy, but there are nevertheless 
common elements according to market conditions, obstacles and potentials of the country. Many are intended 
to improve coordination between national and international actors working on joint projects and encourage 
strategies that mitigate the obstacles caused by the problems described above.  
 
Biotech companies in India have sought ways to establish partnerships with multinational 
corporations, with a view to enhancing the credibility of small businesses and increasing the chances of forming 
potential partnerships. Through service contracts and partnerships with large companies, organizations and 
laboratories in other countries some of these companies conduct clinical trials or perform very specific 
production processes within a longer production chain, or develop joint-venture projects. Others choose to 
become subsidiaries of companies with greater technological and financial capacity, not only to access new 
financial resources but also technology, experience and know-how, at the same time achieving access to markets 
in other countries (Frew, S. et al., 2007). It is claimed that these strategies not only allow small businesses to 
access technology, knowledge and valuable experience, they also reduce the risk involved in major investments 
and increase the chance of obtaining approval from care research centers in developing countries. Through these 
agreements, for instance, Indian companies have been authorized to develop vaccines jointly with institutions 
in Canada, the US and the Netherlands; others have managed to get a laboratory certification by the College of 
American Pathologists (Northfield, IL, USA); some have succeeded in conducting tests for multinational 
companies such as Merck (USA), AstraZeneca (London) and Pfizer (USA), and a number of them have been 
able to work with technology from the International Center of Research for Diarrheal Disease, to develop 
vaccines against cholera (Frew, S. et al. (2007).  
 
For multinational companies such agreements are often attractive when small companies have relevant 
information and experience concerning the legal, bureaucratic and administrative processes of the country 
concerned, or when the multinational is particularly interested in entering that market, or wishes to participate 
in local projects or invest in markets with potential for revenues that may be considered investment projects.  
 
In Argentina and Brazil the overall organizational structure has been strengthened with a view to 
encouraging coordination between academia, government and business to generate synergies both among 
themselves and also with other sectors, seeking to provide relevant and useful information for entrepreneurs, 
scientists and consumers, and facilitate contact with the representatives responsible for specific issues in the 
different ministries, institutions and agencies. Furthermore, according to Zylberberg, C. et al. (2012), Argentina 
has defined strategic areas of impact for biotech developments: agribusiness, health, energy and social 
development, where researchers cooperate on specific projects with other prestigious institutions around the 
world such as the Max Planck Institute, the CERN laboratories, the Pierre Auger Observatory and SIASGE 
space program. Moreover, Argentina has entered into bilateral agreements with other countries seeking to 
further empower and leverage these projects.  
 
Finally, mention should be made of the increased creation of biotech clusters, which concentrate the 
development of the sector in regions, research and development processes, knowledge, technology and efforts 
to access funding sources, facilitating joint projects among actors, encouraging cooperation, and facilitating 
access to legal advice and procedures, among others. Their existence, however, does not guarantee success for 
the subsequent development of the sector, to the extent that innovation activities depend not only on the physical 
proximity of their agents, but also on market structures, competition, the ability to convert knowledge into 
marketable goods and services, as well as the impact of the regulation of the balance of power among the actors 
involved, and a variety of additional factors (Zeller, C., 2001). Colombia is currently studying the feasibility of 
creating such a cluster, but so far has only conducted preliminary market studies, which suggests that its creation 
could be viable.  
  
4. Conclusions 
 
Main findings indicate that the market is the domain of the private sector, with a large number of small 
businesses whose number easily exceeds that of the multinational companies, but hold a minor market share, in 
a scenario where multinationals represent an oligopolistic structure and command the largest proportion of 
worldwide sales. 
 
In the Colombian case, local companies dominate the market with a 73% share. However, the majority 
of these companies are small in size, and are the large companies and multinationals who actually control the 
market, generating 73% of the sector’s jobs and contributing 83% of total production. One of the negative 
consequences of this distribution, is associated with the multinationals’ modus operandi: In general, these 
businesses only import processed products that are locally packaged for sale to the Colombian market, and 
create an environment that prevents the generation of spillover effects, particularly in terms of knowledge and 
technology transfer, based on the management of intellectual property rights and patents, that discourage the 
development of the domestic biotechnology industry.  
 
Companies’ potential for development depends largely on the institutional environment within which 
they operate. This is because of the administrative procedures, legal requirements, need to find sources of 
financing and the coordination of a large number of agents, among other aspects, that are required to reach the 
commercialization stage. In this sense, the institutions of control established in the market where the company 
is located can exert a powerful influence. In Latin America, the main obstacles to progress caused by 
institutional and regulatory frameworks in countries such as Argentina, Brazil and Colombia are associated 
with government and market shortcomings arising from: the scarcity of resources; difficulties in increasing 
investments in infrastructure and applied research, and other financial constraints; lack of coordination between 
academia, the private sector and the government aimed at channeling research activities towards strategic areas 
and focusing research on satisfying market needs; excessive costs in terms of administrative red tape and 
difficulties in marketing scientific discoveries; in many cases, the absence of a specialized body in 
multidisciplinary areas that mitigates coordination problems and asymmetric information and that expedites 
cumbersome procedures for research centers and biotechnology companies.  
 
These situations denote coordination failures and serve to increase investors’ uncertainty and 
perception of risk, which at the same time, is prone to generate strong asymmetries of information between the 
scientific communities of developed and developing countries. 
 
Upon reviewing the business strategies employed to promote the development of the biotechnology 
sector, it was found that each country develops its own differentiated strategy, but there are nevertheless 
common elements according to market conditions, obstacles and potentials of the country. Many are intended 
to improve coordination between national and international actors working on joint projects and encourage 
strategies that mitigate the obstacles caused by the problems described above, as is the case of the increased 
creation of biotech clusters, which concentrate the development of the sector in regions, research and 
development processes, knowledge, technology and efforts to access funding sources, facilitating joint projects 
among actors, encouraging cooperation, and facilitating access to legal advice and procedures, among others. 
It is important to highlight that the existence of such cluster does not guarantee success for the subsequent 
development of the sector. 
 
References 
 
Castellanos, O.; Carrillo, A.; Castro, F.; Jiménez, C. (2011). Análisis conceptual y metodológico de la 
innovación tecnológica. Caso: empresas representativas del sector biotecnológico. Revista Ingeniería 
y Competitividad, 2011, vol. 4, no 1, pp 55-68.  
 
Colciencias (2008). La Biotecnología, motor de desarrollo para la Colombia de 2015. Grupo Biogestión de la 
Universidad Nacional de Colombia and CorpoGen, Bogotá, D.C., Colombia.  
 
Defrancesco, E.; Runge, F. (2006). Exclusion, Inclusion, and Enclosure: historical commons, and modern 
intellectual property. World Development (34) 10: pp 1713 – 1727.  
 
Foros Semana (2011). Memorias del Foro en Biotecnología y Bionegocios, Foros Semana, Bogotá.  
 
Frew, Sara; Rezaie, Rahim; Sammut, Stephen; Ray, Monali; Daar, Abdallah; Singer, Peter (2007). India's health 
biotech sector at a crossroads. Nature Biotechnology, 25(4), pp 403-418. 
http://dx.doi.org/10.1038/nbt0407-403 
 
González, C.; Villa, J.; Velasco, R. (2007). Biotecnología: desde el punto de vista de los negocios. 
http://www.unicauca.edu.co/biotecnologia/ediciones/vol5/4Vol5.pdf (Accessed on June 8, 2011).  
 
González, J. (2011). Herramientas de Financiación para Proyectos que involucren Bio-Diversidad de 
Cosméticos y Productos de Aseo. Universidad Externado de Colombia, Faculty of Finance, 
Government and International Relations. 
http://www.andi.com.co/Archivos/file/Cosmeticos/Clase%20Mundial/BOLETIN10/PrptaUExternad
o.pdf (Accessed on July 9, 2011).  
 
Innpulsa Colombia (2013) – Programa de Transformación Productiva [PTP]. Estudio sobre el potencial de la 
industria de biotecnología en el país. 
https://www.ptp.com.co/documentos/Estudio%20Potencial%20de%20las%20Industria%20de%20Bi
otecnologia%20en%20el%20Pais%20Parte%20C.pdf (Accessed on July 14, 2013)  
 
Juma, Calestous; Honca, Derya (2002). Biotechnology and the precautionary principle. International Journal of 
Biotechnology, 4(1), pp 1-3. http://dx.doi.org/10.1504/IJBT.2002.000175 
 
OCDE - Festel Capital (2010). Industry Structure and Business Models for Industrial Biotechnology Research 
Methodology and Results for Discussion. OECD workshop on the Outlook on Industrial 
Biotechnology, Vienna, January 14, 2010.  
 
OC&T (2012) Indicadores de Ciencia y Tecnología Colombia 2010. 
http://ocyt.org.co/informes_indicadores/Indicadores_OCyT_2012/html/index.html (Accessed on July 
29, 2011).  
 
Pearse, Noel (2007). The Role of Experience in the Creation of Intellectual Capital.” In Proceedings of the 4th 
International Conference on Intellectual Capital, Knowledge Management and Organizational 
Learning (p. 329). Academic Conferences Limited.  
 
Pinilla, Edwin (2004). Herramientas para la competitividad a partir del uso de la biotecnología. Economía y 
Desarrollo, volumen 3, Número 2. http://www.fuac.edu.co/revista/II/II/seis.pdf (Accessed on June 15, 
2011).  
 
Zeller, Christian (2001). Clustering biotech: A recipe for success? Spatial patterns of growth of biotechnology 
in Munich, Rhineland and Hamburg. Small Business Economics, 17(1-2), pp 123-141. 
http://dx.doi.org/10.1023/A:1011182624329 
 
Zylberberg, Claudia; Oner, Asli; Zylberberg, Ezequiel (2012). Biotechnology in Argentina: Development and 
Resources. Journal of Commercial Biotechnology, 18(3). http://dx.doi.org/10.5912/jcb528 
 
Zylberberg, Claudia; Oner, Asli; Zylberberg, Ezequiel. (2012). Biotechnology in Brazil: An Industry Overview. 
Journal of Commercial Biotechnology, 18(4). http://dx.doi.org/10.5912/jcb542 
